Wattlestone has made an investment in Brisbane based start up which is developing a product platform for the emergency treatment of life-threatening conditions through the need to get life-saving drugs to patients faster when they are experiencing conditions such as anaphylaxis and cardiac arrest out of hospital.
The company founded by Professor John Fraser and Chaired by John Eales is on a clear path to be recognised as a global leader, innovator and disrupter for patient centric emergency care solutions through redefining the gold standard of treatment through development and launch of innovative technologies that ultimately save lives.
The current first line treatment in the market is the application of Adrenaline which rapidly reverses the effects of anaphylaxis with the current standard being administered via intramuscular injection as soon as possible via an auto-injector by the patient themselves or a bystander. There are approximately 29,000 food induced anaphylactic reactions in the US each year, costing the US economy $25 billion each year with up to 84% of adrenaline auto injectors being used incorrectly.
The technology being developed by De Motu Cordis is a medical device utilising patented inhalation technology to provide emergency treatment utilising the pulmonary pathway to deliver life saving medications via the lungs. Due to the surface area of the lungs being approximately 50 times larger than the area of the patients skin, medications rapidly absorb into the blood stream providing fast and effective treatment.
For more information, please visit De Motu Cordis
